Abata in the News Abata Therapeutics to Present at Upcoming Investor and Industry Events in June Press Release May 31, 2023 We Now Know the Enemy: A Conversation with Richard Ransohoff, M.D. Featuring John Maraganore, Ph.D. Abata Video April 10, 2023 Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity Trends in Immunology March 30, 2023 Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors March 9, 2023 Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis Press Release December 14, 2022 Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer Press Release December 7, 2022 Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day Press Release November 9, 2022 Samantha Singer Named as 2022 PharmaVoice 100 Honoree September 8, 2022 Abata Therapeutics to Present at Upcoming September Investor Conferences Press Release August 31, 2022 Abata Therapeutics to Participate in the Guggenheim I&I Spotlight Series – Treg-Based Therapies Press Release July 7, 2022 Load More
